SuperworthArdelyx profit margin ARDX
Gross, operating and net profit as a share of revenue over the last twelve months, from 2013.
- Net margin, 12 months
- −12.4%
- Operating margin, 12 months
- −7.9%
- Net margin on a year earlier
- +2.2 pts
- Peer median
- 11.6%
Over the twelve months to Jun 30, 2026, Ardelyx kept −12.4% of its revenue as net profit, with an operating margin of −7.9% and a gross margin of 94.4%.
The median for 10 large drugmakers of a similar size is 11.6%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −15.1% | −10.1% | 90.3% |
| FY2024 | −11.7% | −8.4% | 84.8% |
| FY2023 | −53.1% | −50.8% | 85.7% |
| FY2022 | n/a | n/a | 92.1% |
| FY2021 | n/a | n/a | 90.1% |
| FY2020 | n/a | n/a | 98.1% |
| FY2019 | n/a | n/a | n/a |
| FY2018 | n/a | n/a | 82.1% |
| FY2017 | n/a | n/a | n/a |
| FY2016 | n/a | n/a | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | −10.2% | −4.9% | n/a |
| FY2013 | −22.7% | −9.9% | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −12.4% | +2.2 pts | −7.9% | |
| Q1 FY26 | −13.6% | +1.3 pts | −8.7% | |
| Q4 FY25 | −15.1% | −3.4 pts | −10.1% | |
| Q3 FY25 | −14.2% | +14.6 pts | −9.5% | |
| Q2 FY25 | −14.6% | +16.4 pts | −10.5% | |
| Q1 FY25 | −14.9% | +26.5 pts | −11.0% | |
| Q4 FY24 | −11.7% | +41.4 pts | −8.4% | |
| Q3 FY24 | −28.8% | −9.0 pts | −25.4% | |
| Q2 FY24 | −31.0% | +36.7 pts | −28.0% | |
| Q1 FY24 | −41.4% | n/a | −38.9% | |
| Q4 FY23 | −53.1% | n/a | −50.8% | |
| Q3 FY23 | −19.8% | n/a | −17.2% |
Against its peers
Companies in Drug Manufacturers - General nearest Ardelyx's size, closest first, today.
| Company | Profit margin |
|---|---|
| ARDXArdelyx | −12.4% |
| COLLCollegium Pharmaceutical | 5.9% |
| ABUSArbutus Biopharma | 84.2% |
| CRMDCorMedix | 40.5% |
| ZVRAZevra Therapeutics | 42.8% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| PBYIPuma Biotechnology | 11.6% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| OMEROmeros | n/m |
| ARVNArvinas | 2.9% |
| PCRXPacira BioSciences | 2.0% |
| Peer median | 11.6% |
Where Ardelyx ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Ardelyx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.